Abstract
THE ANTIBIOTIC, dactinomycin, and the alkaloid, vincristine sulfate, have each produced objective tumor regression in children with a variety of malignant neoplasms.<sup>1</sup>The best responses to dactinomycin have occurred in cases of Wilms' tumor and rhabdomyosarcoma, although tumor regression has occasionally been observed in children with lymphoma, neuroblastoma, and other neoplasms. The antitumor spectrum of vincristine sulfate has included lymphomas, Wilms' tumor, rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma, retinoblastoma, and liposarcoma. Dactinomycin acts by binding the guanine moiety of deoxyribonucleic acid and thereby preventing the formation of the enzyme, ribonucleic acid polymerase.<sup>2</sup>As a result, ribonucleic acid and protein synthesis are suppressed and cellular damage occurs. Although the specific mechanism of action of vincristine sulfate is unknown, it prevents cell division by interfering in some way with the formation of organization of the spindle tubules of the mitotic apparatus.<sup>3</sup> Since the limiting toxic effect of dactinomycin therapy is most
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
